“Malaria defeated the international community many years ago. We cannot allow this to happen again. A single global action plan for malaria control, that enjoys partnership-wide support, is a strong factor for success,” said Margaret Chan, Director-General of the World…
Increased attention on product human risk and smaller media coverage of drug donations have challenged Pharmaceuticals' ethical reputation last year, states a report published today by Geneva-based research firm Covalence — Covalence Pharmaceutical Industry Report 2008. The pharmaceutical industry dropped…
L'accès aux médicaments dans les pays en voie de développement est un des grands défis posé actuellement aux entreprises pharmaceutiques. Conscients du problème, Ethos et plusieurs investisseurs institutionnels soutiennent le projet « Index sur l'Accès aux Médicaments ». Cette initiative…
Comme catholique croyant, Daniel Vasella, président du Conseil d'administration de Novartis SA, s’est exprimé à Lucerne sur la responsabilité sociale d'une grande entreprise comme la sienne et sur ses engagements en faveur du tiers-monde. La conférence a suscité un vif…
Novartis today announced the opening of a new research institute in Siena with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world. The Novartis Vaccines Institute for Global Health (NVGH) is the…
Heart-related illnesses due to high blood pressure present enormous medical, human and economic costs. Strokes, heart attacks and end-stage renal disease are preventable with tight blood pressure control. Controlling high blood pressure with antihypertensive medications benefits the individual and society…
Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical…
New Delhi/Geneva, August 6, 2007 — The landmark decision by the High Court in Chennai to uphold India's Patents Act in the face of the challenge by Swiss pharmaceutical company Novartis is a major victory for patients' access to affordable…
Mumbai, India, August 6, 2007 - A decision issued today in an Indian court will have long-term negative consequences for research and development into better medicines for patients in India and abroad. The High Court in Chennai dismissed the writ…
Unless delegates to a high-profile summit on diabetes in Kenya last week knew it had been paid for by the world's biggest maker of insulin, they would have been none the wiser when they left. The conference, in the lush…
